A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292Phase 3Recruiting
- Lead sponsor
- Ascentage Pharma Group Inc. (Industry)
- Enrollment
- 486 (estimated)
- Start date
- 11 Jun 2024
- Primary completion
- 25 May 2028 (estimated)
- Study completion
- 26 Mar 2029
- Last update posted
- 25 Nov 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- APG-2575(Lisaftoclax ) Drug
- Placebo Other
- Azacitidine Injection Drug
Conditions and primary outcome
- Acute Myeloid Leukemia
Primary outcome
Overall Survival（OS） (Up to 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06389292.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06389292 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.